Evidence map›Paper›PMID 32238120›Full record

ArticleThe Libyan journal of medicine2020

Drug-resistant tuberculosis: an experience from Qatar.

Maisa Ali, Faraj Howady, Waqar Munir, Hanfa Karim, Zubaida Al-Suwaidi, Muna Al-Maslamani, Abdullatif Alkhal, Nada Elmaki, Hisham Ziglam

Abstract read
In one paragraph

Article in The Libyan journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. A Saudi Arabian Public Health Perspective of Tuberculosis.International journal of environmental research and public health · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maisa AliDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Faraj HowadyDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Waqar MunirDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Hanfa KarimDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Zubaida Al-SuwaidiNational Tuberculosis Reference Laboratory, Hamad Medical Corporation, Doha, Qatar.
Muna Al-MaslamaniDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Abdullatif AlkhalDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Nada ElmakiDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.
Hisham ZiglamDepartment of Infectious Disease, Communicable Diseases Centre, Hamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was conducted to evaluate the characteristics, treatment outcome and risk factors associated with 223 drug-resistant tuberculosis (DR-TB) cases in the State of Qatar. A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010 - March 2015. Demographic, clinical data, drug-resistance pattern of isolated mycobacteria and treatment outcome was assessed for the patient who completed their treatment in Qatar. Of 3301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to at least one drug. The overall prevalence of multi-d rug resistant TB (MDR-TB) was 1.2% (n = 38) of patients. A former resident of Indian sub contents was the most common demographic characteristic observed (64.1%). The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment. Cure and relapse rates were 97.6%, and 2.4%, respectively. Drug-resistant TB in Qatar is influenced by migration where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug-susceptibility testing should be the standard of care.

Indexed as

Antitubercular AgentsFemaleHumansMaleMicrobial Sensitivity TestsMycobacterium tuberculosisPatient IsolationPrevalenceQatarRecurrenceRetrospective StudiesRisk FactorsSputumTransients and MigrantsTreatment OutcomeTuberculosis, Multidrug-ResistantAntitubercular AgentsExtra-Pulmonary TBMDR-TBPulmonary TBRifampicinXDR-TB

Identifiers

PMID32238120
PMCPMC7170354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.